MX362375B - Extracto de saliva entera de sanguijuela. - Google Patents
Extracto de saliva entera de sanguijuela.Info
- Publication number
- MX362375B MX362375B MX2015003352A MX2015003352A MX362375B MX 362375 B MX362375 B MX 362375B MX 2015003352 A MX2015003352 A MX 2015003352A MX 2015003352 A MX2015003352 A MX 2015003352A MX 362375 B MX362375 B MX 362375B
- Authority
- MX
- Mexico
- Prior art keywords
- leech
- treat
- whole
- extract
- methods
- Prior art date
Links
- 241000545744 Hirudinea Species 0.000 title abstract 8
- 239000000284 extract Substances 0.000 title abstract 6
- 210000003296 saliva Anatomy 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 206010067171 Regurgitation Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 208000030852 Parasitic disease Diseases 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 235000006708 antioxidants Nutrition 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
- 238000010792 warming Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agronomy & Crop Science (AREA)
- Biotechnology (AREA)
Abstract
La presente invención se refiere a el uso de una cantidad eficaz de un extracto de saliva entera de una sanguijuela en la fabricación de un medicamento para el tratamiento de hipoglucemia diabética, en donde el extracto se obtiene al: alimentar con un agente fagoestimulador a la sanguijuela; inducir una regurgitación en la sanguijuela en un medio que tiene una temperatura de menos de 0°C; recolectar una saliva entera no refinada en la regurgitación de la sanguijuela fría; separar componentes sólidos de la saliva entera no refinada para crear, una saliva entera refinada; y, liofilizar el extracto de saliva entera.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261701735P | 2012-09-17 | 2012-09-17 | |
US13/624,847 US8685462B1 (en) | 2012-09-17 | 2012-09-21 | Whole, leech saliva product and applications thereof |
PCT/IB2013/002848 WO2014049447A2 (en) | 2012-09-17 | 2013-09-17 | A whole, leech saliva extract |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015003352A MX2015003352A (es) | 2015-10-22 |
MX362375B true MX362375B (es) | 2019-01-14 |
Family
ID=48876315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015003352A MX362375B (es) | 2012-09-17 | 2013-09-17 | Extracto de saliva entera de sanguijuela. |
Country Status (10)
Country | Link |
---|---|
US (17) | US8501241B1 (es) |
EP (1) | EP2895178B1 (es) |
JP (1) | JP6220398B2 (es) |
CN (1) | CN104837495A (es) |
AU (1) | AU2013322269B2 (es) |
CA (1) | CA2882533A1 (es) |
ES (1) | ES2710126T3 (es) |
IN (1) | IN2015DN02729A (es) |
MX (1) | MX362375B (es) |
WO (1) | WO2014049447A2 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8501241B1 (en) | 2012-09-17 | 2013-08-06 | Biopep Solutions, Inc. | Treating cancer with a whole, leech saliva extract |
KR101341289B1 (ko) * | 2013-07-09 | 2013-12-12 | 한선대 | 거머리 타액의 채취방법 |
CN104151425B (zh) * | 2014-08-15 | 2017-02-08 | 周维海 | 一种天然水蛭素的规模化生产方法 |
CN104365560A (zh) * | 2014-10-29 | 2015-02-25 | 颍上县永祥旱粮研究所 | 一种水蛭的养殖方法 |
CN105418756B (zh) * | 2015-12-25 | 2018-12-21 | 汤浩强 | 一种水蛭唾液重复提取的方法 |
CN105594666B (zh) * | 2015-12-25 | 2020-04-03 | 贵州信邦制药股份有限公司 | 一种快速增加水蛭抗凝血酶活性的养殖方法 |
CN108210523A (zh) * | 2016-12-09 | 2018-06-29 | 江苏小潘园生态农业科技发展有限公司 | 一种水蛭酒的制作方法 |
CN107129962B (zh) * | 2017-05-18 | 2019-03-05 | 中国计量大学 | 一种日本医蛭唾液腺细胞的原代培养方法 |
CN107519036A (zh) * | 2017-09-06 | 2017-12-29 | 深圳肽之妃科技有限公司 | 一种含多肽的妊娠纹喷剂及其制备方法 |
CN107796183A (zh) * | 2017-11-17 | 2018-03-13 | 广西远程水蛭养殖有限公司 | 水蛭干燥方法 |
CN109528773A (zh) * | 2019-01-15 | 2019-03-29 | 昆明学院 | 水蛭唾液在制备镇痛药物中的应用 |
CN109662984B (zh) * | 2019-02-13 | 2022-07-26 | 昆明医科大学 | 臭灵丹和迷迭香提取物在抗ⅱ型登革病毒药物中的应用 |
US10787338B1 (en) | 2019-08-30 | 2020-09-29 | Blazing Spools LLC | Spool device and related methods |
CN112915106A (zh) * | 2021-02-05 | 2021-06-08 | 张虎山 | 一种肿瘤免疫微环境调控剂的制备及其应用 |
CN113577821B (zh) * | 2021-07-07 | 2022-08-30 | 三峡大学 | 一种活体水蛭素的重复提取装置及方法 |
CN118005739B (zh) * | 2024-04-09 | 2024-06-21 | 南京华盖制药有限公司 | 一种抗耐药菌株的多肽aph229及其制备方法和应用 |
CN118406137B (zh) * | 2024-07-01 | 2024-09-06 | 云南云蛭康生物科技有限公司 | 一种用于采集水蛭唾液提取物的装置 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4588587A (en) | 1983-03-01 | 1986-05-13 | Pennsylvania Hospital | Method of treatment to inhibit metastasis |
JP2566934B2 (ja) | 1985-08-10 | 1996-12-25 | バイオフア−ム(ユ−ケイ)リミテツド | 血小板凝集抑制作用を有するコラ−ゲン特異性酵素 |
US4832849A (en) | 1988-06-16 | 1989-05-23 | Merrell Dow Pharmaceuticals Inc. | Extraction and purification of an anticoagulant principle from the south american leech, haementeria ghilianii |
IL86857A (en) * | 1988-06-24 | 1994-04-12 | Yissum Res Dev Co | Platelet-aggregating inhibitory agents from leech saliva and pharmaceutical preparations containing the same |
GB8826428D0 (en) * | 1988-11-11 | 1988-12-14 | Biopharm Ltd | Antithrombin |
ZA904622B (en) | 1989-06-20 | 1991-03-27 | Merrell Dow Pharma | Ghilanten:antimetastatic principle from the south american leech,haementeria ghilanii |
AU624962B2 (en) | 1989-06-20 | 1992-06-25 | Merrell Dow Pharmaceuticals Inc. | Ghilanten: antimetastatic principle from the south american leech, haementeria ghilanii |
DE4103649A1 (de) | 1991-02-07 | 1992-08-13 | Basf Ag | Neue antikoagulatorisch wirksame peptide |
AU659432B2 (en) | 1991-03-08 | 1995-05-18 | Novartis Ag | A method for the inhibition or prevention of tumor cell metastasis with hirudin |
DE4209110A1 (de) | 1991-11-26 | 1993-05-27 | Basf Ag | Neue thrombininhibitorische proteine aus landblutegeln |
DE4234921A1 (de) | 1992-10-16 | 1994-04-21 | Basf Ag | Neues, die Gerinnungszeit des Blutes verlängerndes Protein aus dem Landblutegel Haemadipsa sylestris |
JPH08511157A (ja) | 1993-04-09 | 1996-11-26 | バイオ − テクノロジー・ジェネラル・コーポレーション | Xaファクター阻害活性を有する新規ポリペプチド |
GB9309509D0 (en) | 1993-05-07 | 1993-06-23 | Merck Patent Gmbh | Thrombin inhibitors |
WO1995004750A1 (en) | 1993-08-09 | 1995-02-16 | Athena Neurosciences, Inc. | Tick derived protease inhibitor |
WO1997017981A1 (en) * | 1995-11-13 | 1997-05-22 | Gerard Voerman | Anti-viral isolates obtainable from leeches |
US5866120A (en) | 1995-11-22 | 1999-02-02 | Advanced Corneal Systems, Inc. | Method for accelerating clearance of hemorrhagic blood from the vitreous humor with hyaluronidase |
US6610292B2 (en) | 1995-11-22 | 2003-08-26 | Ista Pharmaceuticals, Inc. | Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders |
EP0875564A1 (en) | 1997-05-02 | 1998-11-04 | Gerard Voerman | Biologically active extract from the leech 'Limnatis nilotica' |
SE512633C2 (sv) | 1997-07-09 | 2000-04-17 | Cecilia Johnsson | Användning av hyaluronidas för reduktion av inflammatoriska cellinfiltrat |
CN1355850A (zh) | 1999-06-12 | 2002-06-26 | 默克专利股份有限公司 | 来源于马尼拉水蛭的透明质酸酶,分离、纯化和重组生产方法 |
JP2004536835A (ja) | 2001-07-09 | 2004-12-09 | アフトン コーポレーション | 肝臓、肺および食道の癌性ならびに前癌性状態の治療および防止 |
CN1273012C (zh) * | 2003-01-15 | 2006-09-06 | 周维海 | 从菲牛蛭活体中提取天然水蛭素的方法 |
CN101230086A (zh) * | 2007-01-22 | 2008-07-30 | 广东海洋大学 | 一种以菲牛蛭唾液为原材料的水蛭素生产工艺 |
WO2009018640A1 (en) | 2007-08-07 | 2009-02-12 | Universidade Federal De São Paulo Unifesp | Use of platelet aggregation and coagulation inhibitors isolated from bauhinia sp. |
WO2009120186A1 (en) | 2008-03-24 | 2009-10-01 | Carolus Therapeutics, Inc. | Methods and compositions for treating atherosclerosis and related conditions |
EP2316465A1 (en) | 2009-10-15 | 2011-05-04 | Centre National De La Recherche Scientifique | Use of extract of leeches' saliva as anti-bacterial agent for the manufacture of different compositons |
CN102258771A (zh) | 2011-07-13 | 2011-11-30 | 中国药科大学 | 重组水蛭素在防治糖尿病性白内障中的应用 |
US8501241B1 (en) | 2012-09-17 | 2013-08-06 | Biopep Solutions, Inc. | Treating cancer with a whole, leech saliva extract |
CN102964446B (zh) * | 2012-11-28 | 2014-08-13 | 周维官 | 一种吸血水蛭活体多次提取天然水蛭素方法 |
-
2012
- 2012-09-21 US US13/624,870 patent/US8501241B1/en active Active
- 2012-09-21 US US13/624,856 patent/US8790711B2/en active Active
- 2012-09-21 US US13/624,847 patent/US8685462B1/en active Active
- 2012-09-21 US US13/624,860 patent/US8784896B2/en active Active
-
2013
- 2013-09-17 WO PCT/IB2013/002848 patent/WO2014049447A2/en active Application Filing
- 2013-09-17 EP EP13841434.7A patent/EP2895178B1/en active Active
- 2013-09-17 IN IN2729DEN2015 patent/IN2015DN02729A/en unknown
- 2013-09-17 AU AU2013322269A patent/AU2013322269B2/en not_active Ceased
- 2013-09-17 MX MX2015003352A patent/MX362375B/es active IP Right Grant
- 2013-09-17 CA CA2882533A patent/CA2882533A1/en not_active Abandoned
- 2013-09-17 JP JP2015531659A patent/JP6220398B2/ja not_active Expired - Fee Related
- 2013-09-17 ES ES13841434T patent/ES2710126T3/es active Active
- 2013-09-17 CN CN201380048148.6A patent/CN104837495A/zh active Pending
-
2014
- 2014-05-20 US US14/282,865 patent/US8932642B2/en active Active
- 2014-05-20 US US14/282,893 patent/US8962034B2/en active Active
- 2014-11-24 US US14/552,388 patent/US9005667B1/en not_active Expired - Fee Related
- 2014-12-08 US US14/563,829 patent/US9017732B1/en not_active Expired - Fee Related
-
2015
- 2015-03-13 US US14/657,671 patent/US9149498B2/en not_active Expired - Fee Related
- 2015-03-26 US US14/670,262 patent/US9144587B2/en not_active Expired - Fee Related
- 2015-08-25 US US14/835,485 patent/US9265802B2/en not_active Expired - Fee Related
- 2015-08-27 US US14/837,281 patent/US9265803B2/en not_active Expired - Fee Related
- 2015-12-23 US US14/757,765 patent/US9433648B2/en active Active
-
2016
- 2016-01-08 US US14/991,023 patent/US9433649B2/en active Active
- 2016-07-28 US US15/222,180 patent/US9480720B1/en active Active
- 2016-07-29 US US15/223,352 patent/US9597361B2/en active Active
-
2017
- 2017-02-07 US US15/426,576 patent/US10064897B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2015DN02729A (es) | ||
PH12017501306A1 (en) | Inhibitors of histone demethylases | |
MX2013006040A (es) | Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis. | |
MX2016001587A (es) | Inhibidores de kdm1a para el tratamiento de enfermedades. | |
CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
MX2015016983A (es) | Moduladores del transporte nuclear y usos de los mismos. | |
CO6440531A2 (es) | 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso | |
NZ702663A (en) | Nuclear transport modulators and uses thereof | |
JO3776B1 (ar) | التركيبات الصيدلانية لمثبط CDK4 / 6 ومثبط B-Raf | |
MX2013004061A (es) | Analogos de ciclosporina. | |
BR112012028711A2 (pt) | métodos para a fabricação de uma emulsão de óleo em água, para a preparação de um kit de vacina e para redestilação de uma composição compreendendo 99% de esqualeno ou mais, assim como emulsão de óleo em água e kit | |
EP3878445A3 (en) | Acamprosate formulations, methods of using the same, and combinations comprising the same | |
BR112012032008A2 (pt) | anticorpos s100a4 e usos terapêuticos do mesmo | |
MX2014000829A (es) | Particulas que comprenden un principio activo a base de poliacrilato. | |
CL2014003325A1 (es) | Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer | |
MX2013004062A (es) | Analogos de ciclosporina. | |
WO2014165723A3 (en) | Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells | |
NZ701133A (en) | Composition for treating metabolic disorders | |
MX343517B (es) | 2,4 pirimidinadiaminas sustituidas para su uso en lupus discoide. | |
WO2014100857A8 (en) | Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy | |
MX2014006574A (es) | Formulaciones de acamprosato, metodos de uso de las mismas, y combinaciones que comprenden las mismas. | |
WO2012108748A3 (ko) | 합환피 추출물을 포함하는 뇌암 치료용 조성물 및 화장료 조성물 | |
CL2008001615A1 (es) | Compuestos derivados de di(hetero)aril-ciclohexano; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cardiopatias, arritmias, isquemias, entre otras. | |
TN2014000484A1 (en) | Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis. | |
UA41802U (ru) | Средство для лечения саркоптоидозов животных |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |